Bafetinib Hydrochloride

N/A

Report date: 2022/11/25 16:34:12
NME

Base Information

Drug NameBafetinib Hydrochloride
Drug Alias Name巴非替尼盐酸盐bafetinibum盐酸巴氟替尼bafetinib巴氟替尼盐酸盐 +[10] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBcr-Abl tyrosine kinase inhibitorsTyrosine-protein kinase Lyn inhibitors
TargetsTyrosine-protein kinase LynBcr-Abl tyrosine kinase
Therapy Area/IndicationsHormone-Resistant Prostate NeoplasmsNeoplasm MetastasisBrain Neoplasms +[12] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesGermanyIsrael
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesCytrx Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCytrx CorpNational Cancer Institute
Active IndicationsN/A
Inactive IndicationsHormone-Resistant Prostate NeoplasmsNeoplasm MetastasisBrain Neoplasms +[12] 

Other Information

ATC CodeN/A
Related LinksWikipedia